02:51 PM EDT, 03/13/2025 (MT Newswires) -- Akebia Therapeutics ( AKBA ) shares were down more than 14% in recent Thursday trading after the biopharmaceutical company reported a wider-than-expected Q4 loss.

Earlier, the company reported a Q4 net loss of $0.10 per diluted share. Analysts polled by FactSet expected a loss of $0.08.

Revenue for the quarter ended Dec. 31 was $46.5 million, down from $56.2 million a year earlier. Analysts surveyed by FactSet expected $37.3 million.

The company said it has sufficient funds to run its current operating plan for at least two years.

Price: 1.65, Change: -0.29, Percent Change: -14.77